ClinicalTrials.gg
RecruitingNCT06062212Updated Nov 5, 2026

Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO

An observational study in Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation and Mechanical Power, sponsored by Beijing Chao Yang Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Beijing Chao Yang Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Respiratory Distress Syndrome with a site in China — 54 open to participants now, 55 under way, 6 of them phase 3. Respiratory Distress Syndrome · China.

Planned enrollment
41st of 65
100 · median 139
Started
2023
with 22 others
Observational
65 of 146
22 open now
Primary completion
2027-12
later than 43 of 54 live
Registered
98th of 146
by date
Lead sponsor
6 of 146
Beijing Chao Yang Hospital

Among the 146 studies in Respiratory Distress Syndrome with a site in China, this one is the 41st largest by planned enrollment of the 65 observational ones that give a count, is one of 23 that started in 2023, is one of 65 observational ones, reaches primary completion later than 43 of the 54 other live ones, and was the 98th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

54 of the 146 studies in Respiratory Distress Syndrome with a site in China are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Respiratory Distress Syndrome with a site in China, or all of them as a file.
02

Study summary

Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a salvage treatment for severe acute respiratory distress syndrome (ARDS). With the large-scale implementation of VV-ECMO in critical care medicine departments in China, significant progress has been made in treating severe ARDS. However, the patient mortality rate remains high. The pathophysiological essence of ARDS is an imbalance between the body's oxygen supply and demand, causing tissue and cell hypoxia, organ dysfunction, and even death. The VV-ECMO treatment process still requires mechanical ventilation assistance. However, inappropriate mechanical ventilation settings can lead to ventilator-related lung injury (VILI). In recent years, mechanical power has gradually attracted everyone's attention and is considered the cause of VILI. The transpulmonary mechanical power is more accurate to the energy directly performed to the lung tissue. Transpulmonary mechanical energy has a specific value in judging the prognosis of mechanically ventilated patients, but its clinical significance in treating patients with VV-ECMO is unclear. This study aimed to explore the value of transpulmonary mechanical power in predicting the prognosis of patients with severe ARDS patients treated with VV-ECMO.

03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Extracorporeal Membrane Oxygenation
  • Mechanical Power
  • Transpulmonary Mechanical Power
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Severe ARDS patients treated with VV-ECMO

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the diagnostic criteria of Berlin's definition for ARDS;
  2. Receiving VV-ECMO support.

Exclusion criteria

Exclusion Criteria:

  1. Patients had been on high pressure (Ppeak >35 cm H2O) and a high fraction of inspired oxygen (FiO2>0.8) ventilation for >7 days;
  2. Patients had a to heparinization;
  3. Patients had an irreversible neurological injury;
  4. Patients had severe chronic lung disease with \<6 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Transpulmonary pressure group

    Procedure: Transpulmonary pressure

Interventions

  • ProcedureTranspulmonary pressure

    Use transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.

06

What researchers measure

Primary outcomes

  1. Patients successfully weaned from VV-ECMO

    Weaning VV-ECMO more than 48 hours with stable oxygenation and no need to re-establish ECMO

    Time frame: After patients enrolled 60 days

Secondary outcomes

  1. 60-day mortality

    Mortality rate at 60 days of VV-ECMO support

    Time frame: After patients enrolled 60 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2027, 50 months after the start.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 50 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 2, 2023
StartActual
Oct 1, 2023
Primary completionEst.
Dec 30, 2027was Dec 2025
CompletionEst.
Apr 30, 2028was Dec 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 30, 2025→Dec 30, 2027
Nov 5, 2026
Study completion
Dec 31, 2025→Apr 30, 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 30, 2025→Dec 30, 2027
    Study completion Dec 31, 2025→Apr 30, 2028
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06062212
Responsible party
Rui Wang (Principal Investigator, Beijing Chao Yang Hospital) — Principal investigator
First posted
Oct 2, 2023
Start date
Oct 1, 2023
Primary completion
Dec 30, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Yu Zhao, Dr.
Contact
xuanben1985@163.com
+8618601342030
Rui Wang, Dr.
study director · Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion